Citi reiterates buy rating on Arcus Biosciences after stock drops 20%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Citi reiterates buy rating on Arcus Biosciences after stock drops 20%
October 21, 2026 4:22 PM EDT
Arcus Biosciences, Inc. (NYSE: RCUS) has commenced an underwritten public offering of its common stock, with all shares being offered by the company, according to a press release statement.
The biopharmaceutical company also intends to grant underwriters a 30-day option to... More
October 21, 2026 7:05 AM EDT
(Updated - October 21, 2026 9:22 AM EDT)
Truist Securities analyst Supawat Thongthip raised the price target on Arcus Biosciences (NYSE: RCUS) to $41.00 (from $40.00) while maintaining a Buy rating.
The analyst commented: "More Than Meets the Eye, with PEAKs Ahead; RCUS disclosed updated... More
October 21, 2026 3:56 AM EDT
Citi analyst Yigal Nochomovitz raised his price target on Arcus Biosciences (NYSE: RCUS) to $50 from $45, while maintaining a Buy rating on the stock.
The revision follows Arcus Biosciences' investor event, where updated data on casdatifan, the company's drug candidate for clear cell renal... More
October 20, 2026 1:32 PM EDT
Wedbush analyst Robert Driscoll raised the price target on Arcus Biosciences (NYSE: RCUS) to $49.00 (from $43.00) while maintaining a Outperform rating.... More
October 20, 2026 9:12 AM EDT
Investing.com -- Arcus Biosciences (NYSE: RCUS) shares fell 6% today after the company presented new clinical data for casdatifan, its investigational HIF-2 inhibitor, at an investor event in New York City. The market decline suggests the data did not meet elevated expectations that had been priced... More
